CF
Carma Fund
Activity from announced rounds
Activity in this selectionOct 19, 2026 · Sep 20, 2026
Carma Fund is the investment brand named in the Allogenetics and Exciva financing histories.
Recorded funding activity
Allogenetics develops an ex vivo gene-therapy approach that modifies donor organs before transplantation to reduce rejection. Exciva develops therapies for behavioral symptoms associated with Alzheimer’s disease. The covered announcements use the unnumbered brand; they do not identify a particular fund vintage.
- Rounds participated in
- 0
- Confirmed lead rounds
- — All roles disclosed
- New companies
- 0 First participation on record · 0 follow-on
- Funding in participating rounds
- — 0 disclosed · full round size, not this investor’s share
By stage
No activity in this selection.
By primary sector
No activity in this selection.
By country
No activity in this selection.
Rounds
0 in this selectionNo rounds match this selection.